Raymond James & Associates Foghorn Therapeutics Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Raymond James & Associates holds 2,297,319 shares of FHTX stock, worth $11.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,297,319
Previous 2,338,423
1.76%
Holding current value
$11.5 Million
Previous $13.4 Million
59.08%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding FHTX
# of Institutions
80Shares Held
33.3MCall Options Held
8.7KPut Options Held
2.4K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$63.6 Million20.03% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$26.6 Million1.57% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.03MShares$15.2 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$8.69 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY1.57MShares$7.9 Million1.62% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $209M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...